#1 Clinical Trials Search in Europe

Gsk4011499

This article discusses a clinical trial investigating the use of GSK4011499, a novel capsid inhibitor, in the treatment of HIV-1 infection. The study aims to assess the drug’s antiviral effects, safety, tolerability, and pharmacokinetics in treatment-naïve adults with HIV-1. This research is an important step in developing new therapies for HIV-1 and potentially improving treatment options for patients.

Table of Contents

What is GSK4011499?

GSK4011499 is a new medication being studied for the treatment of HIV-1 infection. It is currently in the experimental stage and is being tested in a clinical trial to determine its effectiveness and safety[1]. HIV-1 (Human Immunodeficiency Virus type 1) is the most common type of HIV, which attacks the body’s immune system and can lead to AIDS if left untreated.

How Does GSK4011499 Work?

GSK4011499 belongs to a class of drugs called capsid inhibitors. The capsid is a protein shell that protects the genetic material of the HIV virus. By targeting this capsid, the drug aims to interfere with the virus’s ability to replicate and spread in the body[1]. This approach is different from other commonly used HIV medications, potentially offering a new way to combat the virus.

Clinical Trial Details

The clinical trial for GSK4011499 is a Phase 2 study, which means it’s testing the drug’s effectiveness and safety in a larger group of people after initial safety has been established[1]. Here are some key points about the trial:

  • It’s a randomized, double-blind, placebo-controlled trial. This means participants are randomly assigned to either receive the drug or a placebo (a pill with no active ingredient), and neither the participants nor the researchers know who is getting which until the study is over[1].
  • The main goal is to evaluate how well GSK4011499 reduces the amount of HIV-1 in the blood (viral load) over 10 days of treatment[1].
  • The study will also look at the safety and tolerability of the drug, as well as how it’s processed by the body (pharmacokinetics)[1].

Who Can Participate in the Study?

The study is looking for specific types of participants. Here are some of the main criteria:

  • Adults aged 18 to 65 years[1]
  • People who are generally healthy apart from their HIV-1 infection[1]
  • Those who have never received treatment for HIV before (treatment-naïve), although prior use of oral PrEP (Pre-Exposure Prophylaxis) is allowed[1]
  • Participants must have a certain level of HIV-1 in their blood and a specific number of CD4+ T-cells (a type of immune cell affected by HIV)[1]

There are also several conditions that would prevent someone from participating, such as pregnancy, certain other infections, or specific health issues[1].

What to Expect During the Trial

The trial is divided into different parts:

  1. Participants will receive either GSK4011499 or a placebo for 10 days[1].
  2. After the 10-day period, all participants will start on standard HIV treatment (combination antiretroviral therapy)[1].
  3. The total study period is 39 days, during which participants will have regular check-ups and tests[1].

Throughout the study, researchers will monitor the amount of HIV in participants’ blood, check for any side effects, and measure how the drug is processed by the body[1].

Potential Benefits and Risks

As with any clinical trial, there are potential benefits and risks to consider:

Potential Benefits:

  • Access to a new, potentially effective HIV treatment before it’s widely available
  • Close medical monitoring throughout the study
  • Contributing to the advancement of HIV treatment research

Potential Risks:

  • Possible side effects from the medication, which are not yet fully known
  • The possibility of receiving a placebo instead of the active drug for the first 10 days
  • The time commitment and potential discomfort from frequent medical tests and visits

It’s important to note that all participants will receive standard HIV treatment after the initial 10-day period, ensuring that everyone gets appropriate care for their HIV infection[1].

Aspect Details
Drug Name GSK4011499
Drug Class Capsid Inhibitor
Study Type Phase 2, Randomized, Double-Blind, Placebo-Controlled
Primary Objective Evaluate antiviral activity over 10 days
Secondary Objectives Assess safety, tolerability, pharmacokinetics, and exposure-response relationship
Participant Criteria HIV-1 infected, treatment-naïve adults, 18-65 years old, CD4+ count ≥200 cells/µL
Treatment Duration 10 days of GSK4011499 or placebo, followed by standard antiretroviral therapy
Key Measurements Change in plasma HIV-1 RNA, adverse events, pharmacokinetic parameters

FAQ

  • What is GSK4011499? GSK4011499 is a new drug being studied as a potential treatment for HIV-1 infection. It belongs to a class of drugs called capsid inhibitors, which work by interfering with the HIV virus's ability to replicate.
  • Who is eligible to participate in this clinical trial? The trial is open to adults aged 18-65 who have documented HIV-1 infection, are treatment-naïve (have not received previous HIV treatment), and have a CD4+ T-cell count of 200 cells/µL or higher. Participants must also be generally healthy apart from their HIV-1 infection.
  • How long does the trial treatment last? The initial treatment with GSK4011499 or placebo lasts for 10 days. After this period, participants will start a standard combination antiretroviral therapy through Day 39 of the study.
  • What are the main goals of this clinical trial? The primary objective is to evaluate the antiviral activity of GSK4011499 over 10 days. Secondary objectives include assessing the drug's safety and tolerability, characterizing its pharmacokinetic profile, and determining the relationship between drug exposure and changes in HIV-1 RNA levels in the blood.
  • Are there any specific exclusion criteria for the trial? Yes, some exclusion criteria include: being pregnant or breastfeeding, having untreated syphilis, testing positive for hepatitis B or C, having certain psychiatric or medical conditions, or using prohibited medications or vaccines. The study also excludes people with acute HIV infection or active CDC Stage 3 disease.

Ongoing Clinical Trials on Gsk4011499

  • Study on the Effects of GSK4004280 and GSK4011499 in Adults with HIV Infections

    Not recruiting

    2 1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy Spain

Glossary

  • Capsid Inhibitor: A type of drug that interferes with the HIV virus's capsid, which is a protein shell that protects the virus's genetic material. By targeting the capsid, these drugs aim to prevent the virus from replicating.
  • Treatment-Naïve: Refers to patients who have never received treatment for a particular condition. In this context, it means people who have never taken HIV medications before.
  • CD4+ T-cell count: A measure of the number of CD4 T lymphocytes (a type of white blood cell) in a person's blood. This count is an important indicator of immune system health in people with HIV.
  • Plasma HIV-1 RNA: The amount of HIV genetic material (RNA) present in a person's blood plasma. This measurement is used to determine the level of HIV in the body, also known as viral load.
  • Pharmacokinetics: The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and excreted. This information helps determine the appropriate dosing and timing of medication.
  • Monotherapy: Treatment using a single drug. In this trial, GSK4011499 is initially given as monotherapy to assess its individual effects before combining it with other HIV medications.
  • Antiretroviral Therapy: A combination of medications used to treat HIV infection. It typically includes three or more drugs from different classes to effectively suppress the virus.
  • Adverse Events (AEs): Any unfavorable or unintended sign, symptom, or disease that occurs during a clinical trial, whether or not it's related to the treatment being studied.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effects-of-gsk4004280-and-gsk4011499-in-adults-with-hiv-infections/